Patients whose tumours showed ER/HER2 negativity, and high OPN and low ALCAM expression (group 2) turned out to be the group having the highest risk for shorter DFS and OAS compared with all the other groups regardless of the administered therapy (see Table 2d and e). Here, ALCAM is linked to neoplasm.